Categories: News

NYSE Content Advisory: Pre-Market Update + Exzeo Celebrates Recent IPO

NEW YORK, Nov. 24, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Ashley Mastronardi delivers the pre-market update on November 24th

- Advertisement -
  • Stocks open higher Monday as Wall Street begins a holiday-shortened trading week, following Friday’s rally where the S&P 500 rose about 1% and the Dow gained nearly 500 points.
  • Rate cut expectations grow after NY Fed President John Williams signaled “further adjustment” to interest rates; traders largely anticipate a 25-basis-point cut at the Fed’s December 10 policy meeting.
  • September Producer Price Index and U.S. retail sales reports due Tuesday; meanwhile, Exzeo celebrates its IPO by ringing the NYSE opening bell, with CEO Paresh Patel featured on the podium.

Opening Bell
Exzeo (NYSE: XZO) celebrates its initial public offering

- Advertisement -

Closing Bell
Mitsubishi UFJ Financial Group (NYSE: MUFG) celebrates the 20th anniversary of founding

- Advertisement -

Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2830924/NYSE_Market_Update_16_9_Nov_24.mp4
Logo – https://mma.prnewswire.com/media/2581322/New_York_Stock_Exchange_Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–exzeo-celebrates-recent-ipo-302624556.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

3 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

3 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

3 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

3 hours ago